Status:
COMPLETED
The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis
Lead Sponsor:
Mayo Clinic
Conditions:
Fungal Infection
Candidiasis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to investigate the role of the human immune response to candidemia/invasive candidiasis as it relates to the cytokine interferon-gamma.
Detailed Description
In this study, patients with Candida bloodstream infection, peritonitis/intra-abdominal abscess, and pleural empyema will be enrolled. Persistent candidiasis confirmed by culture will be defined as f...
Eligibility Criteria
Inclusion
- Subjects must meet all following inclusion criteria to qualify for the study:
- Willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally authorized representative must provide informed consent on his/her behalf.
- Males or females ≥18 years of age
- Patients having one or more systemic signs attributable to candidemia or invasive candidiasis (fever, hypothermia, hypotension, tachycardia, tachypnea, local signs of inflammation).
- Isolation of Candida from blood, intra-abdominal abscess/peritoneal fluid or pleural fluid.
- Exclusion Criteria
- Subjects must NOT meet any of the following exclusion criteria to qualify for the study:
- Severe neutropenia (absolute neutrophil count \<500 cells/microL)
- Profound lymphopenia (\<300 cells/microL)
- The Principal Investigator (PI) is of the opinion the subject should not participate in the study.
- Females who are pregnant.
Exclusion
Key Trial Info
Start Date :
February 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT05235711
Start Date
February 10 2022
End Date
August 31 2024
Last Update
October 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905